Skip to content

Study · Systematic review · 2024

7 results

Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials.

Lütkemeyer C, Pasqualotto E, Ferreira ROM, Chavez MP, Petris I Jr, Dos Santos HV, Wille JM, Hohl A, Ronsoni MF, van de Sande-Lee S

Archives of endocrinology and metabolism11 Sept 2024Cited by 9 (Europe PMC)

PMID39420937 (opens in a new tab)PMCIDPMC11460968 (opens in a new tab)DOI10.20945/2359-4292-2023-0469 (opens in a new tab)PepBankPUB-39420937
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

The aim of this study is to assess the effects of once-daily oral orforglipron on weight and metabolic markers in adult patients. PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched until February 2024 for randomized controlled trials (RCTs) comparing orforglipron versus placebo or other anti-obesity medications in adult patients. Weighted mean differences (WMDs) for continuous outcomes and risk ratios (RRs) or risk differences for binary endpoints were computed, with 95% confidence intervals (CIs). Heterogeneity and risk of bias were assessed with I2 statistics and Rob-2, respectively. Statistical analyses were performed using R, version 4.2.2. A total of four studies were included, comprising 815 patients, of whom 620 (76.1%) were prescribed orforglipron. Compared with placebo, orforglipron reduced body weight (WMD -6.14 kg, 95% CI -9.62 to -2.66 kg), body mass index (WMD -2.87 kg/m2, 95% CI -4.65 to -1.10 kg/m2), and waist circumference (WMD -5.32 cm, 95% CI -9.13 to -1.51 cm). More patients treated with orforglipron than placebo achieved a weight loss of ≥ 5% (RR 3.31, 95% CI 2.23-4.93), ≥ 10% (RR 5.24, 95% CI 2.07-13.31), and ≥ 15% (RR 9.53, 95% CI 1.26-71.89). The most common adverse events were related to the gastrointestinal tract. In this meta-analysis, the use of once-daily oral orforglipron by adult patients was associated with a significant decrease in body weight, as compared with placebo, with an increase in non-severe gastrointestinal adverse events. Phase 3 RCTs are expected to shed further light on the efficacy and safety of once-daily oral orforglipron over the long term.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults, orforglipron reduced body weight versus placebo by a weighted mean difference of 6.14 kg.

    In plain wordsOrforglipron reduced weight versus placebo by a weighted mean difference of 6.14 kg in adults.

    Peptide
    Orforglipron
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Weighted mean difference
    −6.14 kg
    orforglipron vs placebo, body weight
    95% confidence interval for body weight weighted mean difference
    −9.62 to −2.66 kg
    orforglipron versus placebo, body weight

    Source sentences

    Summary
    Compared with placebo, orforglipron reduced body weight (WMD -6.14 kg, 95% CI -9.62 to -2.66 kg), body mass index (WMD -2.87 kg/m2, 95% CI -4.65 to -1.10 kg/m2), and waist circumference (WMD -5.32 cm, 95% CI -9.13 to -1.51 cm).
    2 context sentences
    Summary · context
    The aim of this study is to assess the effects of once-daily oral orforglipron on weight and metabolic markers in adult patients.
    Summary · context
    PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched until February 2024 for randomized controlled trials (RCTs) comparing orforglipron versus placebo or other anti-obesity medications in adult patients.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults, orforglipron reduced BMI versus placebo by a weighted mean difference of 2.87 kg/m².

    In plain wordsOrforglipron reduced BMI versus placebo by a weighted mean difference of 2.87 kg/m² in adults.

    Peptide
    Orforglipron
    Outcome
    DecreaseBMI
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Weighted mean difference
    −2.87 kg/m<sup>2</sup>
    orforglipron vs placebo, BMI
    95% confidence interval for BMI weighted mean difference
    −4.65 to −1.1 kg/m<sup>2</sup>
    orforglipron versus placebo, BMI

    Source sentences

    Summary
    Compared with placebo, orforglipron reduced body weight (WMD -6.14 kg, 95% CI -9.62 to -2.66 kg), body mass index (WMD -2.87 kg/m2, 95% CI -4.65 to -1.10 kg/m2), and waist circumference (WMD -5.32 cm, 95% CI -9.13 to -1.51 cm).
    2 context sentences
    Summary · context
    The aim of this study is to assess the effects of once-daily oral orforglipron on weight and metabolic markers in adult patients.
    Summary · context
    PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched until February 2024 for randomized controlled trials (RCTs) comparing orforglipron versus placebo or other anti-obesity medications in adult patients.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults, orforglipron reduced waist circumference versus placebo by a weighted mean difference of 5.32 cm.

    In plain wordsOrforglipron reduced waist circumference versus placebo by a weighted mean difference of 5.32 cm in adults.

    Peptide
    Orforglipron
    Outcome
    DecreaseWaist circumference
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Weighted mean difference
    −5.32 cm
    orforglipron vs placebo, waist circumference
    95% confidence interval for waist circumference weighted mean difference
    −9.13 to −1.51 cm
    orforglipron versus placebo, waist circumference

    Source sentences

    Summary
    Compared with placebo, orforglipron reduced body weight (WMD -6.14 kg, 95% CI -9.62 to -2.66 kg), body mass index (WMD -2.87 kg/m2, 95% CI -4.65 to -1.10 kg/m2), and waist circumference (WMD -5.32 cm, 95% CI -9.13 to -1.51 cm).
    2 context sentences
    Summary · context
    The aim of this study is to assess the effects of once-daily oral orforglipron on weight and metabolic markers in adult patients.
    Summary · context
    PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched until February 2024 for randomized controlled trials (RCTs) comparing orforglipron versus placebo or other anti-obesity medications in adult patients.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults, more orforglipron patients than placebo patients achieved at least 5% weight loss, with a risk ratio of 3.31.

    In plain wordsMore adults achieved at least 5% weight loss with orforglipron than placebo, with a risk ratio of 3.31.

    Peptide
    Orforglipron
    Outcome
    IncreaseWeight loss at least 5%
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Risk ratio
    3.31
    orforglipron vs placebo, weight loss of at least 5%
    95% confidence interval for weight loss of at least 5% risk ratio
    2.23 to 4.93
    orforglipron versus placebo, weight loss of at least 5%

    Source sentences

    Summary
    More patients treated with orforglipron than placebo achieved a weight loss of ≥ 5% (RR 3.31, 95% CI 2.23-4.93), ≥ 10% (RR 5.24, 95% CI 2.07-13.31), and ≥ 15% (RR 9.53, 95% CI 1.26-71.89).
    2 context sentences
    Summary · context
    The aim of this study is to assess the effects of once-daily oral orforglipron on weight and metabolic markers in adult patients.
    Summary · context
    PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched until February 2024 for randomized controlled trials (RCTs) comparing orforglipron versus placebo or other anti-obesity medications in adult patients.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults, more orforglipron patients than placebo patients achieved at least 10% weight loss, with a risk ratio of 5.24.

    In plain wordsMore adults achieved at least 10% weight loss with orforglipron than placebo, with a risk ratio of 5.24.

    Peptide
    Orforglipron
    Outcome
    IncreaseWeight loss at least 10%
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Risk ratio
    5.24
    orforglipron vs placebo, weight loss of at least 10%
    95% confidence interval for weight loss of at least 10% risk ratio
    2.07 to 13.31
    orforglipron versus placebo, weight loss of at least 10%

    Source sentences

    Summary
    More patients treated with orforglipron than placebo achieved a weight loss of ≥ 5% (RR 3.31, 95% CI 2.23-4.93), ≥ 10% (RR 5.24, 95% CI 2.07-13.31), and ≥ 15% (RR 9.53, 95% CI 1.26-71.89).
    2 context sentences
    Summary · context
    The aim of this study is to assess the effects of once-daily oral orforglipron on weight and metabolic markers in adult patients.
    Summary · context
    PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched until February 2024 for randomized controlled trials (RCTs) comparing orforglipron versus placebo or other anti-obesity medications in adult patients.
  6. 06HumanSystematic reviewEfficacy outcome

    In adults, more orforglipron patients than placebo patients achieved at least 15% weight loss, with a risk ratio of 9.53.

    In plain wordsMore adults achieved at least 15% weight loss with orforglipron than placebo, with a risk ratio of 9.53.

    Peptide
    Orforglipron
    Outcome
    IncreaseWeight loss at least 15%
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Risk ratio
    9.53
    orforglipron vs placebo, weight loss of at least 15%
    95% confidence interval for weight loss of at least 15% risk ratio
    1.26 to 71.89
    orforglipron versus placebo, weight loss of at least 15%

    Source sentences

    Summary
    More patients treated with orforglipron than placebo achieved a weight loss of ≥ 5% (RR 3.31, 95% CI 2.23-4.93), ≥ 10% (RR 5.24, 95% CI 2.07-13.31), and ≥ 15% (RR 9.53, 95% CI 1.26-71.89).
    2 context sentences
    Summary · context
    The aim of this study is to assess the effects of once-daily oral orforglipron on weight and metabolic markers in adult patients.
    Summary · context
    PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched until February 2024 for randomized controlled trials (RCTs) comparing orforglipron versus placebo or other anti-obesity medications in adult patients.
  7. 07HumanSystematic reviewSafety outcome

    In the adult orforglipron studies, gastrointestinal events were the most common adverse events.

    In plain wordsDigestive events were the most common adverse events in the adult orforglipron studies.

    Peptide
    Orforglipron
    Outcome
    Not applicableGastrointestinal adverse events
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    The most common adverse events were related to the gastrointestinal tract.
    2 context sentences
    Summary · context
    The aim of this study is to assess the effects of once-daily oral orforglipron on weight and metabolic markers in adult patients.
    Summary · context
    PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched until February 2024 for randomized controlled trials (RCTs) comparing orforglipron versus placebo or other anti-obesity medications in adult patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.